医学
免疫疗法
回顾性队列研究
肿瘤科
内科学
肺
队列研究
队列
肿瘤进展
无进展生存期
细胞
总体生存率
生存分析
临床试验
梅德林
作者
Qi He,Xiaobei Guo,Yu‐rou Chen,Xiaoxing Gao,Minjiang Chen,Jing Zhao,Wei Zhong,Yan Xu,Mengzhao Wang
出处
期刊:Thoracic Cancer
[Wiley]
日期:2025-10-01
卷期号:16 (20): e70173-e70173
被引量:6
标识
DOI:10.1111/1759-7714.70173
摘要
BACKGROUND: In metastatic non-small cell lung cancer (NSCLC) patients receiving first-line immune checkpoint inhibitors (ICIs), the real-world progression patterns and subsequent treatment outcomes remain controversial. METHODS: We retrospectively analyzed patients with stage IV NSCLCs treated with first-line immunotherapy between January 2017 and June 2023. Clinico-demographic and treatment data were obtained from an electronic medical record system. Progression patterns were categorized by: (1) Progression in different organs; (2) Progression in existing or new lesions; and (3) Oligoprogression versus systemic progression. Survival was assessed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Among 157 patients, 67.5% experienced systemic progression, and 49.0% had progression in existing lesions. The most common organs with progression were the lung (81.5%), lymph nodes (35.0%), and pleural effusion (24.2%). Median post-progression survival (PPS) was superior in oligoprogression versus systemic progression (22.4 vs. 10.9 months, p = 0.012). Patients with extrapulmonary progression (8.2 vs. 22.9 months, p < 0.001) or progression in new lesions (9.6 vs. 25.3 months, p = 0.029) showed decreased PPS. In multivariate Cox regression, ECOG PS of 2-4 (HR: 2.26, p = 0.003), tumor stage of IVB (HR: 1.74, p = 0.013), and extrapulmonary progression (HR: 2.05, p = 0.002) were associated with decreased PPS. Subsequent treatments containing ICIs improved survival compared to regimens without ICIs (29.0 vs. 11.3 months, p = 0.004), particularly in patients with systemic progression (19.3 vs. 9.2 months, p = 0.013). CONCLUSION: Most metastatic NSCLCs on first-line immunotherapy experienced systemic progression. Oligoprogression and progression only in existing lesions showed better prognoses, whereas extrapulmonary progression indicated worse survival. Subsequent ICI-containing treatments had improved survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI